title: Is imatinib still the best choice as first-line oral TKI.
abstract: Targeted therapy is the buzz word these days. A decade back the emergence of tyrosine kinase inhibitor Imatinib on the horizon, as the targeted therapy, had captured the imagination of everyone in the field of cancer. It is encouraging to see a large number of patients getting relief from deadly CML disease and leading a good quality of life with the help of this drug. However, sky is not the limit and now we have second and third generation tyrosine kinase inhibitors. I still remember the sagacious smile on the face of late Dr. John Goldman, when I asked him about his preferred choice and he replied and I quote "this is going to be the debate of the decade." Here I take the opportunity to contribute to this debate. I have scrutinized various aspects of the three TKIs, now recommended, for the treatment of CML. I'm still convinced it is too early to shift our practice completely towards 2G TKI as more time is required to make a clear recommendation.
authors.affiliation: Department of Pediatric Oncology, Asian Institute of Oncology, K J Somaiya Hospital, Sion, Mumbai, Maharashtra, India.
authors.forename: Shweta
authors.initials: S
authors.lastname: Bansal
keywords: Chronic myeloid leukemia; Frontline therapy; imatinib